L. Witte

发表

Studies of the Release from Human Platelets of the Growth Factor for Cultured Human Arterial Smooth Muscle Cells

H. Weiss, D. Goodman, B. Lages, 1978, Circulation research.

Vascular Endothelial Growth Factor (VEGF)-driven Actin-based Motility Is Mediated by VEGFR2 and Requires Concerted Activation of Stress-activated Protein Kinase 2 (SAPK2/p38) and Geldanamycin-sensitive Phosphorylation of Focal Adhesion Kinase*

Jacques Landry, Johannes Waltenberger, J. Landry, 2000, The Journal of Biological Chemistry.

Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis

S. Rafii, R. Crystal, F. Liao, 2004, Nature Medicine.

Release of endothelial cell lipoprotein lipase by plasma lipoproteins and free fatty acids.

I. Goldberg, U. Saxena, L. Witte, 1989, The Journal of biological chemistry.

Hypoxia-mediated induction of acidic/basic fibroblast growth factor and platelet-derived growth factor in mononuclear phagocytes stimulates growth of hypoxic endothelial cells.

M. Matsumoto, D. Pinsky, K. Kuwabara, 1995, Proceedings of the National Academy of Sciences of the United States of America.

Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody.

M. Skobe, D. Hicklin, M. Swartz, 2005, Journal of the National Cancer Institute.

Conservation of receptor antagonist anti-tumor activity by epidermal growth factor receptor antibody expressed in transgenic corn seed.

Peter Bohlen, Dipa Patel, Xiaoqiang Kang, 2004, Human antibodies.

Apoprotein B structure and receptor recognition of triglyceride-rich low density lipoprotein (LDL) is modified in small LDL but not in triglyceride-rich LDL of normal size.

E. Levy, Y. Arad, Y. Marcel, 1994, The Journal of biological chemistry.

Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy

P. Bohlen, Zhen-ping Zhu, Haifan Zhang, 2002, International journal of cancer.

IMC-EB10, an anti-FLT3 monoclonal antibody, prolongs survival and reduces nonobese diabetic/severe combined immunodeficient engraftment of some acute lymphoblastic leukemia cell lines and primary leukemic samples.

D. Hicklin, D. Huso, D. Small, 2006, Cancer Research.

The effects of Flk-2/flt3 ligand as compared with c-kit ligand on short-term and long-term proliferation of CD34+ hematopoietic progenitors elicited from human fetal liver, umbilical cord blood, bone marrow, and mobilized peripheral blood.

S. Rafii, D. Hicklin, M. Moore, 1996, Journal of hematotherapy.

Generation of gene-modified T cells reactive against the angiogenic kinase insert domain-containing receptor (KDR) found on tumor vasculature.

P. Hwu, J. Westwood, M. Kershaw, 2000, Human gene therapy.

Effects of age, exercise and varying thyroxine levels on cardiovascular parameters and cholesterol turnover pools of the rat

L. Witte, 1974 .

Dose-dependent Increases in Circulating Tgf-a and Other Egfr Ligands Act as Pharmacodynamic Markers for Optimal Biological Dosing of Cetuximab and Are Tumor Independent Cancer Therapy: Preclinical

R. Kerbel, M. Moore, Christina R. Lee, 2022 .

Inhibition of Glioblastoma Growth in a Highly Invasive Nude Mouse Model Can Be Achieved by Targeting Epidermal Growth Factor Receptor but not Vascular Endothelial Growth Factor Receptor-2

M. Westphal, Zhen-ping Zhu, C. Hagel, 2008, Clinical Cancer Research.

Prioritization of EGFR/IGF-IR/VEGFR2 combination targeted therapies utilizing cancer models.

D. Hicklin, Zhen-ping Zhu, D. Ludwig, 2009, Anticancer research.

Heterogeneity in storage pool deficiency: studies on granule-bound substances in 18 patients including variants deficient in alpha-granules, platelet factor 4, beta-thromboglobulin, and platelet-derived growth factor.

Kaplan, H. Weiss, D. Goodman, 1979, Blood.

Heparin modulates the interaction of VEGF165 with soluble and cell associated flk-1 receptors.

D. Hicklin, G. Neufeld, B. Levi, 1994, The Journal of biological chemistry.

Localization of VEGF receptor-2 (KDR/Flk-1) and effects of blocking it in oxygen-induced retinopathy.

D. S. Mcleod, Zhen-ping Zhu, G. Lutty, 2002, Investigative ophthalmology & visual science.

Platelet-derived growth factor labeled to colloidal gold for use as a mitogenic receptor probe.

D. Handley, L. Witte, 1984, European journal of cell biology.

Involvement of VEGFR-2 (kdr/flk-1) but not VEGFR-1 (flt-1) in VEGF-A and VEGF-C-induced tube formation by human microvascular endothelial cells in fibrin matrices in vitro

K. Alitalo, D. Hicklin, Yan Wu, 2004, Angiogenesis.

Tumor necrosis factor induced release of endothelial cell lipoprotein lipase.

I. Goldberg, U. Saxena, L. Witte, 1990, Arteriosclerosis.

Tumor necrosis factor-alpha and interleukin-1 antagonists alleviate inflammatory skin changes associated with epidermal growth factor receptor antibody therapy in mice.

U. Rodeck, Yan Wu, K. Busam, 2009, Cancer Research.

Relationship between mevalonate and mitogenesis in human fibroblasts stimulated with platelet-derived growth factor.

D. Goodman, L. Witte, K. Fairbanks, 1984, The Journal of biological chemistry.

Stimulation of arterial endothelial cell prostacyclin synthesis by high density lipoproteins.

A. Tall, P. Cannon, L. Fleisher, 1982, The Journal of biological chemistry.

Role of apolipoprotein E-containing lipoproteins in abetalipoproteinemia.

A. Tall, C. Blum, R. Deckelbaum, 1982, The Journal of clinical investigation.

Inhibition of lymphocyte proliferation stimulated by lectins and allogeneic cells by normal plasma lipoproteins

D. Goodman, L. Witte, J. Morse, 1977, The Journal of experimental medicine.

Effect of Platelet‐Derived Growth Factor on 3‐Hydroxy‐3‐Methylglutaryl Coenzyme A Reductase Activity in Cultured Human Fibroblasts

L. Witte, W. S. Goodman, K. Fairbanks, 1986 .

Effects of mevinolin and mevalonate on cell growth in several transformed cell lines

I. Weinstein, V. Barbu, D. Goodman, 1986, Journal of cellular physiology.

Inhibition of LDL Degradation in Cultured Human Fibroblasts Induced by Endothelial Cell‐Conditioned Medium

D. Goodman, J. Cornicelli, L. Witte, 1983, Arteriosclerosis.

Signaling and Inhibits Human Tumor Growth Growth Factor I Receptor Blocks Ligand-Dependent A Fully Human Monoclonal Antibody to the Insulin-Like Updated

D. Hicklin, P. Bohlen, Zhen-ping Zhu, 2003 .

Monoclonal antibody strategies to block angiogenesis.

D. Hicklin, P. Bohlen, L. Witte, 2001, Drug discovery today.

Suppression of leukemia expressing wild-type or ITD-mutant FLT3 receptor by a fully human anti-FLT3 neutralizing antibody.

D. Hicklin, P. Bohlen, Zhen-ping Zhu, 2004, Blood.

Studies on Cell Proliferation and Mevalonic Acid Metabolism in Cultured Human Fibroblasts a

V. Barbu, D. Goodman, L. Witte, 1985, Annals of the New York Academy of Sciences.

Effects of PDGF and Endothelial Cell Products on Cellular Lipid and Lipoprotein Metabolism in Human Fibroblasts

D. Goodman, L. Witte, K. Fairbanks, 1983 .

Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration.

S. Rafii, K. Hattori, D. Hicklin, 2000, The Journal of clinical investigation.

Heterogeneity in storage pool deficiency: studies on granule-bound substances in 18 patients including variants deficient in alpha- granules, platelet factor 4, beta-thromboglobulin, and platelet-derived growth factor

H. Weiss, D. Goodman, B. Lages, 1979 .

Advances in Brief Inhibition of Vascular Endothelial Growth Factor-induced Receptor Activation with Anti-Kinase Insert Domain-containing Receptor Single-Chain Antibodies from a Phage Display Library

Zhenping, Zhen-ping, Zhu, 2006 .

Identification of the Residues in the Extracellular Region of KDR Important for Interaction with Vascular Endothelial Growth Factor and Neutralizing Anti-KDR Antibodies*

P. Bohlen, Zhen-ping Zhu, P. Kussie, 2000, The Journal of Biological Chemistry.

Acquired antagonistic activity of a bispecific diabody directed against two different epitopes on vascular endothelial growth factor receptor 2.

P. Bohlen, K. Persaud, Z. Zhu, 1999, Journal of immunological methods.

Inhibition of vascular endothelial growth factor induced mitogenesis of human endothelial cells by a chimeric anti-kinase insert domain-containing receptor antibody.

D. Hicklin, P. Bohlen, X. Jimenez, 1999, Cancer letters.

Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity

S. Rafii, K. Hattori, P. Bohlen, 2003, Leukemia.

Hematopoietic activity of a stromal cell transmembrane protein containing epidermal growth factor-like repeat motifs.

K. Moore, I. Lemischka, B. Pytowski, 1997, Proceedings of the National Academy of Sciences of the United States of America.

Inhibition of Both the Autocrine and the Paracrine Growth of Human Leukemia with a Fully Human Antibody Directed Against Vascular Endothelial Growth Factor Receptor 2

D. Hicklin, P. Bohlen, Zhen-ping Zhu, 2004, Leukemia & lymphoma.

Colloidal gold--low density lipoprotein conjugates as membrane receptor probes.

D. Handley, C. Arbeeny, S. Chien, 1981, Proceedings of the National Academy of Sciences of the United States of America.

Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth.

K. Alitalo, D. Hicklin, Takashi Takahashi, 2007, Cancer research.

Involvement of the VEGF receptor 3 in tubular morphogenesis demonstrated with a human anti-human VEGFR-3 monoclonal antibody that antagonizes receptor activation by VEGF-C

Zhen-ping Zhu, K. Persaud, J. Tille, 2004, Journal of Cell Science.

Platelet-derived growth factor stimulates low density lipoprotein receptor activity in cultured human fibroblasts.

J. Cornicelli, L. Witte, 1980, Proceedings of the National Academy of Sciences of the United States of America.

Unesterified fatty acids inhibit the binding of low density lipoproteins to the human fibroblast low density lipoprotein receptor.

B. Bihain, R. Deckelbaum, Y. Carpentier, 1989, The Journal of biological chemistry.

Impaired recruitment of bone-marrow–derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth

S. Rafii, K. Manova, R. Crystal, 2001, Nature Medicine.

Flk 2 ) in human leukemias Expression of the hematopoietic growth factor receptor FLT 3

D. Small, M. Levenstein, C. Carow, 2002 .

Vascular Trauma Induces Rapid but Transient Mobilization of VEGFR2+AC133+ Endothelial Precursor Cells

S. Rafii, D. Hicklin, R. Yurt, 2001, Circulation research.

Clinical development of angiogenesis inhibitors to vascular endothelial growth factor and its receptors as cancer therapeutics.

P. Bohlen, Zhen-ping Zhu, L. Witte, 2002, Current cancer drug targets.

Engraftment and reconstitution of hematopoiesis is dependent on VEGFR2-mediated regeneration of sinusoidal endothelial cells.

Zev Rosenwaks, Shahin Rafii, Daniel J. Nolan, 2009, Cell stem cell.

Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors.

S. Rafii, M. Oz, D. Hicklin, 2000, Blood.

Effect of platelet-derived and endothelial cell-derived growth factors on the low density lipoprotein receptor pathway in cultured human fibroblasts.

R. Miller, D. Goodman, J. Cornicelli, 1982, The Journal of biological chemistry.

A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo.

Peter Bohlen, Dan Lu, D. Hicklin, 2003, Cancer research.

A Fully Human Recombinant IgG-like Bispecific Antibody to Both the Epidermal Growth Factor Receptor and the Insulin-like Growth Factor Receptor for Enhanced Antitumor Activity*

D. Hicklin, P. Bohlen, Zhen-ping Zhu, 2005, Journal of Biological Chemistry.

Simultaneous Blockade of Both the Epidermal Growth Factor Receptor and the Insulin-like Growth Factor Receptor Signaling Pathways in Cancer Cells with a Fully Human Recombinant Bispecific Antibody*

P. Bohlen, Zhen-ping Zhu, Haifan Zhang, 2004, Journal of Biological Chemistry.

Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias.

M. Borowitz, S. Kaufmann, D. Small, 1996, Blood.

Cell-based selection of internalizing fully human antagonistic antibodies directed against FLT3 for suppression of leukemia cell growth

D. Ludwig, H. Li, Z. Zhu, 2005, Leukemia.

Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents.

R. Kerbel, R. Strieter, E. Voest, 2008, Cancer cell.

FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells.

D. Hicklin, Zhen-ping Zhu, D. Ludwig, 2004, Blood.

FLT 3 ligand causes autocrine signaling in acute myeloid leukemia cells

D. Hicklin, Zhen-ping Zhu, D. Ludwig, 2003 .

Inhibitory anti-FLT3 antibodies are capable of mediating antibody-dependent cell-mediated cytotoxicity and reducing engraftment of acute myelogenous leukemia blasts in nonobese diabetic/severe combined immunodeficient mice.

D. Hicklin, Zhen-ping Zhu, D. Ludwig, 2005, Cancer research.

Radiation Damage in Endothelial Cells Autocrine Effects of Fibroblast Growth Factor in Repair of Updated

A. Haimovitz-Friedman, Z. Fuks, I. Vlodavsky, 2006 .

STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells.

M. Ratajczak, D. Small, M. Levenstein, 1994, Proceedings of the National Academy of Sciences of the United States of America.

Anti–Transforming Growth Factor β Receptor II Antibody Has Therapeutic Efficacy against Primary Tumor Growth and Metastasis through Multieffects on Cancer, Stroma, and Immune Cells

Zhen-ping Zhu, Yan Wu, D. Ludwig, 2010, Clinical Cancer Research.

Effects of irradiation on the release of growth factors from cultured bovine, porcine, and human endothelial cells.

A. Haimovitz-Friedman, Z. Fuks, D. Goodman, 1989, Cancer research.

Targeting the platelet-derived growth factor receptor α with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: Implications as a potential therapeutic target

Peter Bohlen, Dan Lu, D. Hicklin, 2005, Molecular Cancer Therapeutics.

Inhibition of both paracrine and autocrine VEGF/ VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias

S. Rafii, D. Hicklin, P. Bohlen, 2001, Proceedings of the National Academy of Sciences of the United States of America.

Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1+ stem cells from bone-marrow microenvironment

S. Rafii, R. Crystal, Z. Werb, 2002, Nature Medicine.

Vascular Endothelial Growth Factor and Angiopoietin-1 Stimulate Postnatal Hematopoiesis by Recruitment of Vasculogenic and Hematopoietic Stem Cells

S. Rafii, R. Crystal, D. Hicklin, 2001, The Journal of experimental medicine.

Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors.

D. Hicklin, P. Bohlen, Y. Li, 1999, Cancer research.

Endothelial cells are essential for the self-renewal and repopulation of Notch-dependent hematopoietic stem cells.

Ian A. White, I. Bernstein, S. Rafii, 2010, Cell stem cell.

Inhibition of Tumor Growth and Metastasis by Targeting Tumor-Associated Angiogenesis with Antagonists to the Receptors of Vascular Endothelial Growth Factor

Zhen-ping Zhu, L. Witte, 2004, Investigational New Drugs.

High density of small vessels expressing the tyrosine kinase receptor KDRin primary invasive breast carcinoma correlates with axillary lymph node metastases

D. Hicklin, J. Papadimitriou, M. Edel, 2004, Angiogenesis.

Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single-chain antibodies from a phage display library.

D. Hicklin, P. Bohlen, Z. Zhu, 1998, Cancer research.

Estimating preclinical efficacy targets utilizing cetuximab efficacy in KRAS mutant and wild-type colorectal cancer models.

K. Paz, Huiling Li, Dhanvanthri S. Deevi, 2011, Anticancer research.

Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro.

J. Mestan, C. Schnell, S. Mandriota, 2001, The Journal of pharmacology and experimental therapeutics.

Glypican-1 Is a VEGF165 Binding Proteoglycan That Acts as an Extracellular Chaperone for VEGF165 *

G. Neufeld, D. Ron, S. Gengrinovitch, 1999, The Journal of Biological Chemistry.

Storage Pool Disease: Evidence for Clinical and Biochemical Heterogeneity

H. Weiss, D. Goodman, B. Lages, 1977, Thrombosis and Haemostasis.

Induction of growth factor genes in endothelial cells by ionizing radiation

A. Haimovitz-Friedman, Z. Fuks, M. McLoughlin, 1995 .

Perturbation of Endothelial Functions by Ionizing Irradiation: Effects on Prostaglandins, Chemoattractants and Mitogens

Z. Fuks, A. Eldor, Y. Matzner, 1989, Seminars in thrombosis and hemostasis.

Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy

D. Hicklin, Zhen-ping Zhu, B. Pytowski, 1998, Cancer and Metastasis Reviews.

Tailoring in Vitro Selection for a Picomolar Affinity Human Antibody Directed against Vascular Endothelial Growth Factor Receptor 2 for Enhanced Neutralizing Activity*

Peter Bohlen, Dan Lu, P. Bohlen, 2003, Journal of Biological Chemistry.

Pleiotropic stromal effects of vascular endothelial growth factor receptor 2 antibody therapy in renal cell carcinoma models.

H. Youssoufian, Michelle Iacolina, J. Tonra, 2011, Neoplasia.

Ultrastructural visualization of low-density lipoproteins during receptor binding and cellular endocytosis.

D. Handley, C. Arbeeny, D. Goodman, 1983, Journal of ultrastructure research.

The vascular endothelial growth factor receptor (VEGFR‐1) supports growth and survival of human breast carcinoma

S. Rafii, D. Hicklin, P. Bohlen, 2006, International journal of cancer.

Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor.

Peter Bohlen, Dan Lu, P. Bohlen, 2001, Cancer research.

A recombinant, fully human, bispecific antibody neutralizes the biological activities mediated by both vascular endothelial growth factor receptors 2 and 3

Dan Lu, Zhen-ping Zhu, K. Persaud, 2005, Molecular Cancer Therapeutics.

DEGA/AMIGO-2, a leucine-rich repeat family member, differentially expressed in human gastric adenocarcinoma: effects on ploidy, chromosomal stability, cell adhesion/migration and tumorigenicity

D. Ludwig, Larry Witte, Dale L Ludwig, 2004, Oncogene.

Low Molecular Weight Fibrinogen Degradation Products Stimulate the Release of Growth Factors from Endothelial Cells

A. Bini, L. Witte, R. Lorenzet, 1992, Thrombosis and Haemostasis.

cDNA cloning, chromosomal mapping, and expression analysis of human VE-Cadherin-2

D. Hicklin, P. Bohlen, E. Dejana, 2000, Mammalian Genome.

Development of a fully human anti-PDGFRbeta antibody that suppresses growth of human tumor xenografts and enhances antitumor activity of an anti-VEGFR2 antibody.

Zhen-ping Zhu, Haifan Zhang, D. Ludwig, 2009, Neoplasia.

The effect of variable domain orientation and arrangement on the antigen-binding activity of a recombinant human bispecific diabody.

Dan Lu, Zhen-ping Zhu, Xenia Jimenez, 2004, Biochemical and biophysical research communications.

Di-diabody: a novel tetravalent bispecific antibody molecule by design.

Peter Bohlen, Dan Lu, P. Bohlen, 2003, Journal of immunological methods.

Vascular Trauma Induces Rapid but Transient Mobilization of VEGFR2+AC133+ Endothelial Precursor Cells

S. Rafii, D. Hicklin, R. Yurt, 2001 .

Abstract 2590: KD019: Blood brain barrier penetrant HER2/neu, Src, and EGFR inhibitor

M. Berger, R. Tilton, J. Ryan, 2015 .

162 In vivo effects of a monoclonal antibody to the murine VEGFR-3 that antagonizes the binding of VEGF-C and receptor signaling

D. Hicklin, M. Swartz, K. Persaud, 2004 .

Cloning, genetic characterization, and chromosomal mapping of the mouse VDUP1 gene.

P. Bohlen, D. Ludwig, L. Witte, 2001, Gene.

Fab-scFv fusion protein: an efficient approach to production of bispecific antibody fragments.

Peter Bohlen, Dan Lu, Zhen-ping Zhu, 2002, Journal of immunological methods.

An efficient route to the production of an IgG-like bispecific antibody.

Zhen-ping Zhu, Zhuang Zuo, Xenia Jimenez, 2000, Protein engineering.

Long-term progression and therapeutic response of visceral metastatic disease non-invasively monitored in mouse urine using β-human choriogonadotropin secreting tumor cell lines

R. Kerbel, Zhen-ping Zhu, Y. Shaked, 2008, Molecular Cancer Therapeutics.

Dose-Dependent Increases in Circulating TGF-α and Other EGFR Ligands Act As Pharmacodynamic Markers for Optimal Biological Dosing of Cetuximab and Are Tumor Independent

R. Kerbel, M. Moore, Christina R. Lee, 2009, Clinical Cancer Research.

Radiation Damage in Endothelial Cells Autocrine Effects of Fibroblast Growth Factor in Repair of Updated

A. Haimovitz-Friedman, Z. Fuks, I. Vlodavsky, 2006 .

Involvement of the VEGF receptor 3 in tubular morphogenesis demonstrated with a human anti-human VEGFR-3 monoclonal antibody that antagonizes receptor activation by VEGF-C

Zhen-ping Zhu, J. Tille, X. Jimenez, 2004 .